GV 143253

Drug Profile

GV 143253

Alternative Names: GV 143253A

Latest Information Update: 04 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antibacterials; Lactams
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 04 Mar 2008 Discontinued - Preclinical for Meticillin-resistant Staphylococcus aureus infections in Italy (Parenteral)
  • 28 Feb 2003 Pharmacokinetics, pharmacodynamics and antimicrobial activity data from a preclinical trial in Methicillin-resistant Staphylococcus aureus infections released by GlaxoSmithKline
  • 16 Apr 1998 Preclinical development for Methicillin-resistant Staphylococcus aureus infections in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top